Delaying Amphotericin B–Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have Zygomycosis
Top Cited Papers
Open Access
- 15 August 2008
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 47 (4), 503-509
- https://doi.org/10.1086/590004
Abstract
Background. Zygomycosis is an emerging opportunistic mycosis among immunocompromised patients with a particularly poor prognosis. Methods. We analyzed the impact of delaying effective amphotericin B–based therapy on outcome among 70 consecutive patients with hematologic malignancy who had zygomycosis in our institution during the period 1989–2006. We used classification and regression tree analysis to identify the mortality breakpoint between early and delayed treatment. Results. Delayed amphotericin B–based therapy (i.e., initiating treatment ⩾6 days after diagnosis) resulted in a 2-fold increase in mortality rate at 12 weeks after diagnosis, compared with early treatment (82.9% vs. 48.6%); this remained constant across the years of the study and was an independent predictor of poor outcome (odds ratio, 8.1; 95% confidence interval, 1.7–38.2; P=.008) in multivariate analysis. Active malignancy (P=.003) and monocytopenia (P=.01) at the time of diagnosis of infection were also independently associated with a poor outcome, whereas salvage posaconazole-based therapy (P=.01) and neutrophil recovery (P=.009) were predictive of a favorable outcome. Conclusions. Because discriminating between zygomycosis and aspergillosis in a timely fashion is difficult, the pursuit of aggressive diagnostic strategies and prompt initiation of antifungal agents with activity against Zygomycetes should be considered for patients with hematological malignancy who are at an increased risk for zygomycosis.Keywords
This publication has 22 references indexed in Scilit:
- Invasive Zygomycosis: Update on Pathogenesis, Clinical Manifestations, and ManagementInfectious Disease Clinics of North America, 2006
- Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 CasesClinical Infectious Diseases, 2006
- Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported CasesClinical Infectious Diseases, 2005
- Zygomycosis in a Tertiary‐Care Cancer Center in the Era ofAspergillus‐Active Antifungal Therapy: A Case‐Control Observational Study of 27 Recent CasesThe Journal of Infectious Diseases, 2005
- Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving VoriconazoleClinical Infectious Diseases, 2004
- Invasive Zygomycosis in Hematopoietic Stem Cell Transplant Recipients Receiving Voriconazole ProphylaxisClinical Infectious Diseases, 2004
- Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell TransplantsThe New England Journal of Medicine, 2004
- Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2002
- Zygomycosis in the 1990s in a Tertiary-Care Cancer CenterClinical Infectious Diseases, 2000
- Zygomycetes in Human DiseaseClinical Microbiology Reviews, 2000